Cetera Investment Advisers Increases Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Cetera Investment Advisers increased its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 0.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 723,840 shares of the biopharmaceutical company’s stock after buying an additional 4,342 shares during the period. Cetera Investment Advisers owned about 0.46% of Ocular Therapeutix worth $6,182,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Atlas Capital Advisors Inc. purchased a new stake in Ocular Therapeutix during the fourth quarter worth about $43,000. AlphaQuest LLC purchased a new position in shares of Ocular Therapeutix in the fourth quarter worth about $53,000. Tower Research Capital LLC TRC increased its stake in shares of Ocular Therapeutix by 2,045.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 8,446 shares in the last quarter. Walleye Capital LLC purchased a new position in shares of Ocular Therapeutix in the fourth quarter worth about $90,000. Finally, XTX Topco Ltd purchased a new position in shares of Ocular Therapeutix in the fourth quarter worth about $99,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Insider Buying and Selling at Ocular Therapeutix

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,475 shares of Ocular Therapeutix stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the completion of the sale, the insider now directly owns 3,520,318 shares in the company, valued at $24,184,584.66. The trade was a 0.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Richard L. Md Lindstrom bought 10,000 shares of the company’s stock in a transaction on Thursday, May 8th. The shares were bought at an average price of $6.96 per share, with a total value of $69,600.00. Following the completion of the transaction, the director now owns 172,704 shares of the company’s stock, valued at $1,202,019.84. The trade was a 6.15% increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

OCUL has been the subject of several recent research reports. JMP Securities set a $19.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. Royal Bank of Canada initiated coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. Needham & Company LLC reduced their target price on shares of Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, May 6th. Finally, William Blair began coverage on shares of Ocular Therapeutix in a research note on Tuesday, April 8th. They issued an “outperform” rating for the company. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $16.25.

Ocular Therapeutix Price Performance

OCUL stock opened at $7.00 on Wednesday. The firm has a 50 day moving average of $7.46 and a 200-day moving average of $8.23. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. Ocular Therapeutix, Inc. has a 12 month low of $4.79 and a 12 month high of $11.78. The firm has a market capitalization of $1.12 billion, a P/E ratio of -5.30 and a beta of 1.51.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The firm had revenue of $17.08 million during the quarter, compared to the consensus estimate of $16.89 million. As a group, sell-side analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.